BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  company  Boehringer Ingelheim International GmbH, Germany submitted on 9 October 1997  to 
the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  an  application  for  the 
marketing  authorisation  of  the  medicinal  product  Micardis  falling  within  the  scope  of  Part  B  of  the 
Annex of the Council Regulation (EEC) 2309/93, of the 22 July 1993.  
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur: 
Prof. S. Garattini 
Co-Rapporteur: 
Prof. A. Hildebrandt 
Licensing status 
Telmisartan was not licensed in any country at the time of submission of the application. 
2. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The procedure started on 27 October 1997. 
The Rapporteur’s assessment report was circulated to all CPMP Members on 19 January 1998. 
The  Co-rapporteur’s  assessment  report  was  circulated  to  all  CPMP  Members  on  19  January 
1998. 
The CPMP consolidated list of questions was adopted on 23 February 1998. 
The responses to CPMP the consolidated list of questions was received on 21 April 1998 
The  joint  Rapporteur-Co-Rapporteur  assessment  report  on  the  responses  to  the  CPMP 
consolidated list of questions was circulated on 26 May 1998. 
During its June 1998 meeting, the CPMP discussed and adopted a list of issues to be addressed 
by the company during a hearing.  
The evaluation clock was stopped on 23 June 1998. 
The  company  submitted  additional  information  regarding  outstanding  points  for  clarification 
regarding quality aspects on 30 June 1998. 
An addendum to the joint Rapporteur-Co-Rapporteur assessment report was received on 7 July 
1998. 
A hearing was held at the CPMP meeting on 21 July 1998, to address the remaining outstanding 
issues.  
The CPMP, during its meeting on 21-23 July 1998, considered the responses provided by the 
company and discussed the recommendations presented by the Rapporteur. Amendments to the 
Summary of Product Characteristics were discussed. 
During the meeting on 21-23 July 1998 the CPMP, in the light of the overall data submitted and 
the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation for Micardis on 23 July 1998. 
The  European  Commission  issued  on  16  December  1998,  a  Marketing  Authorisation  valid 
throughout the European Union. 
                                                                                               1/1 
                                 EMEA 2005 
 
 
 
 
 
 
 
